National Poll: Many parents face challenges getting kids to eat a healthy breakfast before school
Reports and Proceedings
Updates every hour. Last Updated: 29-Oct-2026 01:16 ET (29-Oct-2026 05:16 GMT/UTC)
Glucagon-like peptide 1 receptor agonists (GLP-1RA), commonly known as drugs for diabetes and weight loss, may have additional mental health benefits, especially for people with bipolar disorder, new Griffith University research has found.
A new Cochrane evidence and gap map (EGM) has mapped the global research landscape on dengue prevention, finding plenty of research but not enough of it synthesized in ways policymakers can use.
**Note this is an early release from the Annual Meeting of the European Association for the Study of Diabetes [EASD]. Please credit the meeting when using this research**
Type 2 diabetes has traditionally been a disease that has developed mostly in middle-aged and older adults. But new research from the USA to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows a sharp increase in the rate of new cases of type 2 diabetes since the turn of the century, which has continued to accelerate in recent years. The study is by Dr Tessa Crume, Colorado School of Public Health, Aurora, CO, USA, and colleagues.
A new study published in National Science Review reveals the dual effects of urban greenery on compound heat-ozone pollution risks across Northern Hemisphere cities. While urban greening is widely promoted as a nature-based method to cool overheated cities, complex interactions between urban meteorology and atmospheric chemistry can create important trade-offs for ozone control. The findings call for integrated urban greening strategies that jointly enhance climate resilience, air quality, and public health.
Myopia has become a major global public health concern. It is not simply a matter of blurred distance vision: as the eye continues to elongate, high myopia can increase the risk of macular lesions, choroidal neovascularization, retinal degeneration, and retinal detachment. With myopia rising among children and adolescents, current management increasingly combines behavioral measures, optical interventions, and pharmacological treatment. While atropine has long been the best-known option, uncovering how these medications work to slow myopia progression is far more complex than expected.
A review titled Pharmacological Management of Myopia: Emerging Agents and Novel Molecular Targets published in Eye Discovery brings together current and emerging pharmacological approaches for myopia control. Written by Tong Zhao of Nanjing Medical University and Meiyan Li of the Eye & ENT Hospital of Fudan University, the article reviews established and investigational agents, including atropine, pirenzepine, 7-methylxanthine (7-MX), and intraocular pressure-lowering drugs. It also discusses emerging molecular targets linked to endoplasmic reticulum stress, ferroptosis, signaling pathway modulation, and epidermal growth factor receptor (EGFR) blockade.